Evidence map›Paper›PMID 41799265›Full record

ArticleOpen forum infectious diseases2026

Successful Control of Refractory

Sanjay R Mehta, Scott Johns, Theresa Matkovits, James Ferguson, Joshua Fierer

Abstract readCase Reports
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sanjay R MehtaDepartment of Medicine, San Diego Veterans Affairs Medical Center, San Diego, California, USA.ORCID https://orcid.org/0000-0002-2028-8158
Scott JohnsDepartment of Pharmacy, San Diego Veterans Affairs Medical Center, San Diego, California, USA.
Theresa MatkovitsMatinas Biopharma, Bridgewater, New Jersey, USA.
James FergusonMatinas Biopharma, Bridgewater, New Jersey, USA.
Joshua FiererDepartment of Medicine, San Diego Veterans Affairs Medical Center, San Diego, California, USA.ORCID https://orcid.org/0000-0002-9230-5279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Case Presentation: In 2017 a previously healthy construction worker developed coccidioidal pneumonia and meningitis and was treated with liposomal amphotericin B and oral fluconazole. His pneumonia resolved, but his meningitis worsened. Imaging showed vasculitis of his middle cerebral artery and arachnoiditis at the base of the brain and eventually throughout his spine. He required multiple changes in azoles and eventually an Ommaya reservoir so that he could receive periodic IT amphotericin B plus corticosteroids while continuing oral isavuconazole. Treatment response was monitored with symptoms, cerebral spinal fluid (CSF) cell counts, CSF Conclusions: MAT2203 may offer an oral therapeutic option for refractory cases of

Indexed as

CoccidioidesLNC amphotericinMAT2203meningitisoral amphotericin

Identifiers

PMID41799265
PMCPMC12964188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.